With the high incidence of influenza, oseltamivir, the "magic medicine", has become the object of pursuit, and e-commerce and offline pharmacies in many provinces and cities have ushered in sales peaks or even out of stock.
As the industry leader of oseltamivir, Dongyangguang (600673) Medicine (HK:0 1558) also attracted market attention, and its share price continued to rise. On March 2 1 day, Dongyang Guangyao closed at HK$ 8. 18, up by 108. 14% from the low of HK$ 3.93 on September 22, 2022.
Rely on the performance of oseltamivir to reverse the loss
As early as 2006, Dongyang Guangyao was authorized by Roche Pharmaceutical, the original research and production enterprise of oseltamivir, and became the second authorized enterprise in China after Shanghai Pharmaceutical (60 1607) Group with the trade name of "Kewei".
20 16 with Shanghai pharmaceutical group stopping the production of oseltamivir, Roche pharmaceutical reduced its supply, and Dongyang Guangyao became the largest supplier of oseltamivir in China. In 20 18, oseltamivir was listed in the "Guidelines for the Treatment of Influenza (Version 20 18)" and entered the national list of essential drugs in the same year.
Under many favorable factors, Dongyang Guangyao ushered in continuous growth in performance. In 20 19, the total sales of oseltamivir granules and capsules under Dongyang Guangyao reached 5.939 billion yuan, and the company's total revenue reached the historical peak of 6.948 billion yuan that year.
With the outbreak of COVID-19 epidemic, strict prevention and control measures have greatly reduced the number of influenza cases, and the sales volume of Kewei has plummeted, resulting in the sluggish performance of Dongyang Guangyao. From 2020 to 20021year, the revenue of dongyang guangyao dropped sharply, reaching 2.348 billion yuan and 9140,000 yuan respectively. Net profit turned from profit to loss. The net profit in 2020 was 837 million yuan, lower than 20 19. 202 1, dongyang guangyao lost 588 million yuan.
Due to the good recovery of people flow, diagnosis and treatment activities and drug prescriptions in terminal medical institutions, the performance of Dongyang Guangyao has picked up. On March 17, Dongyang Guangyao announced that it expected to record a net profit of 68 million yuan in 2022.
After the flu concept was fried, the stock price doubled.
The continuous deterioration of performance has also caused Dongyang Guangyao's share price to fall all the way. At the beginning of 2020, the share price of Dongyang Guangyao was still above HK$ 20, and then it went down all the way. 2021165438+13 October, Dongyang Guangyao fell to a record low of HK$ 3.35. Until 2022 10, the share price of dongyang guangyao still fluctuated below hk $5.
Affected by the high incidence of influenza, the concept of anti-influenza has attracted much attention, and the share price of Dongyang Guangyao has continued to rise. In March this year 14, Dongyang Guangyao hit HK$ 8.88, the highest point since July 20021year.
On March 2 1 day, Dongyang Guangyao closed at HK$ 8. 18, double the low of HK$ 3.93 on September 22, 2022.